Date: 2015-10-23
Type of information: Nomination
Compound:
Company: Neurovive Pharmaceutical (Sweden)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 23, 2015, NeuroVive Pharmaceutical announced that Dr. Magnus Hansson will be appointed as Chief Medical Officer, effective as of 1 January 2016. In this role, Dr. Hansson will be responsible for leading clinical research and development activities
around NeuroVive\'s therapeutic candidates and discovery platforms, reporting to Jan Nilsson, interim hief Executive Officer and working closely with CSO Eskil Elmér and the core team of scientists at NeuroVive.
An immediate priority for Dr. Hansson will be to advance NeuroVive\'s leadership position in mitochondrial medicine with a focus on ensuring successful clinical research and development of NeuroVive\'s lead candidates, NeuroSTAT® in traumatic brain injury and CicloMulsion® in acute kidney injury (AKI). NeuroSTAT® is currently being evaluated in a Phase II study in traumatic brain injury. CicloMulsion® is being evaluated in an ongoing Phase II in acute kidney injury. Dr. Hansson will also be involved in progressing products from the discovery platforms into the clinical stage of development.
Dr. Hansson is a long-standing member of NeuroVive\'s scientific team, serving as the primary clinical scientist for the CicloMulsion® studies. Parallel to his previous part-time position at NeuroVive, Dr. Hansson has been serving as a consultant physician and associate professor in medical imaging and physiology at Skåne University Hospital, Sweden. Hansson received his medical degree and PhD in Experimental brain research from Lund University, Sweden and has authored more than 30 scientific publications and 10 patent applications.
Financial terms:
Latest news:
